PacificGMP made the announcement of completing collaboration with LigoCyte Pharmaceuticals, Inc. According to the collaborative agreement, PacificGMP produced master cell and baculovirus banks will provide storage facilities for LigoCyte's norovirus vaccine program under cGMP (current good manufacturing practices) standards. PacificGMP conducted the services under an accelerated timeline.

"We are pleased that LigoCyte chose PacificGMP to produce the master cell and baculovirus banks that will be used to produce their next-generation, intra-muscular norovirus vaccine candidate. The timeline specified in this agreement further demonstrates the time saving advantages of single-use technology as we were able to quickly initiate this project in order to assist LigoCyte in maintaining its program schedule," commented Leigh N. Pierce, President of PacificGMP

Comments

Search RSS

All rights reserved."